This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-1843v1 69/19/7672    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Luistro, L. Articles by Boylan, J. F. PubMed PubMed Citation Articles by Luistro, L. Articles by Boylan, J. F.

Preclinical Profile of a Potent -Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

¹ Discovery Oncology, ² Discovery Chemistry, ³ In Silico Sciences, ⁴ Non-clinical Safety, ⁵ Drug Metabolism, and ⁶ RNA Therapeutics, Hoffmann-La Roche, Inc., Nutley, New Jersey and ⁷ Discovery Chemistry and ⁸ CNS Research, Hoffmann-La Roche, Inc., Basel, Switzerland

Requests for reprints: John F. Boylan, Discovery Oncology, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, NJ 07110. Phone: 973-235-3076; Fax: 973-235-6185; E-mail: john.boylan{at}roche.com.

Notch signaling is an area of great interest in oncology. RO4929097 is a potent and selective inhibitor of -secretase, producing inhibitory activity of Notch signaling in tumor cells. The RO4929097 IC₅₀ in cell-free and cellular assays is in the low nanomolar range with >100-fold selectivity with respect to 75 other proteins of various types (receptors, ion channels, and enzymes). RO4929097 inhibits Notch processing in tumor cells as measured by the reduction of intracellular Notch expression by Western blot. This leads to reduced expression of the Notch transcriptional target gene Hes1. RO4929097 does not block tumor cell proliferation or induce apoptosis but instead produces a less transformed, flattened, slower-growing phenotype. RO4929097 is active following oral dosing. Antitumor activity was shown in 7 of 8 xenografts tested on an intermittent or daily schedule in the absence of body weight loss or Notch-related toxicities. Importantly, efficacy is maintained after dosing is terminated. Angiogenesis reverse transcription-PCR array data show reduced expression of several key angiogenic genes. In addition, comparative microarray analysis suggests tumor cell differentiation as an additional mode of action. These preclinical results support evaluation of RO4929097 in clinical studies using an intermittent dosing schedule. A multicenter phase I dose escalation study in oncology is under way. [Cancer Res 2009;69(19):7672–80]